Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia

Journal of Lipid Research

Volumn 47, Issue 10, 2006, Pages 2333-2339

  Schaap, Frank G ^a   Nierman, Melchior C ^a   Berbée, Jimmy F P ^b   Hattori, Hiroaki ^c   Talmud, Philippa J ^d   Vaessen, Stefan F C ^a   Rensen, Patrick C N ^b   Chamuleau, Robert A F M ^a   Kuivenhoven, Jan Albert ^a   Groen, Albert K ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BML   (Japan)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Apolipoprotein A V; Apolipoprotein C III; Enzyme linked immunosorbent assay; Lipoprotein lipase

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN INTERACTION; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEIN C-III; APOLIPOPROTEINS A; CALIBRATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPERTRIGLYCERIDEMIA; TRIGLYCERIDES;

EID: 33845572471     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M500533-JLR200     Document Type: Article

References (35)

1. Cullen, P. 2000. Evidence that triglycerides are an independent coronary heart disease risk factor. Am. J. Cardiol. 86: 943-949.
2. Mead, J. R., S. A. Irvine, and D. P. Ramji. 2002. Lipoprotein lipase: structure, function, regulation, and role in disease. J. Mol. Med. 80: 753-769.
3. Otarod, J. K., and I. J. Goldberg. 2004. Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr. Atheroscler. Rep. 6: 335-342.
4. Merkel, M., R. H. Eckel, and I. J. Goldberg. 2002. Lipoprotein lipase: genetics, lipid uptake, and regulation. J. Lipid Res. 43: 1997-2006.
5. Koster, A., Y. B. Chao, M. Mosior, A. Ford, P. A. Gonzalez-Dewhitt, J. E. Hale, D. Li, Y. Qiu, C. C. Fraser, D. D. Yang, et al. 2005. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology. 146: 4943-4950.
6. Shimizugawa, T., M. Ono, M. Shimamura, K. Yoshida, Y. Ando, R. Koishi, K. Ueda, T. Inaba, H. Minekura, T. Kohama, et al. 2002. ANGPTL3decreases very lowdensity lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J. Biol. Chem. 277: 33742-33748.
7. van Dijk, K. W., P. C. Rensen, P. J. Voshol, and L. M. Havekes. 2004. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr. Opin. Lipidol. 15: 239-246.
8. Merkel, M., B. Loeffler, M. Kluger, N. Fabig, G. Geppert, L. A. Pennacchio, A. Laatsch, and J. Heeren. 2005. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J. Biol. Chem. 280: 21553-21560.
9. Schaap, F. G., P. C. Rensen, P. J. Voshol, C. Vrins, H. N. van der Vliet, R. A. Chamuleau, L. M. Havekes, A. K. Groen, and K. W. van Dijk. 2004. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein- triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279: 27941-27947.
10. Fruchart-Najib, J., E. Bauge, L. S. Niculescu, T. Pham, B. Thomas, C. Rommens, Z. Majd, B. Brewer, L. A. Pennacchio, and J. C. Fruchart. 2004. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem. Biophys. Res. Commun. 319: 397-404.
11. Pennacchio, L. A., M. Olivier, J. A. Hubacek, J. C. Cohen, D. R. Cox, J. C. Fruchart, R. M. Krauss, and E. M. Rubin. 2001. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 294: 169-173.
12. van der Vliet, H. N., M. G. Sammels, A. C. Leegwater, J. H. Levels, P. H. Reitsma, W. Boers, and R. A. Chamuleau. 2001. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J. Biol. Chem. 276: 44512-44520.
13. van der Vliet, H. N., F. G. Schaap, J. H. Levels, R. Ottenhoff, N. Looije, J. G. Wesseling, A. K. Groen, and R. A. Chamuleau. 2002. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem. Biophys. Res. Commun. 295: 1156-1159.
14. Pennacchio, L. A., M. Olivier, J. A. Hubacek, R. M. Krauss, E. M. Rubin, and J. C. Cohen. 2002. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum. Mol. Genet. 11: 3031-3038.
15. Kao, J. T., H. C. Wen, K. L. Chien, H. C. Hsu, and S. W. Lin. 2003. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum. Mol. Genet. 12: 2533-2539.
16. Olivier, M., X. Wang, R. Cole, B. Gau, J. Kim, E. M. Rubin, and L. A. Pennacchio. 2004. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics. 83: 912-923.
17. Talmud, P. J., E. Hawe, S. Martin, M. Olivier, G. J. Miller, E. M. Rubin, L. A. Pennacchio, and S. E. Humphries. 2002. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum. Mol. Genet. 11: 3039-3046.
18. Oliva, C. P., L. Pisciotta, V. G. Li, M. P. Sambataro, A. Cantafora, A. Bellocchio, A. Catapano, P. Tarugi, S. Bertolini, and S. Calandra. 2005. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 25: 411-417.
19. Marcais, C., B. Verges, S. Charriere, V. Pruneta, M. Merlin, S. Billon, L. Perrot, J. Drai, A. Sassolas, L. A. Pennacchio, et al. 2005. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J. Clin. Invest. 115: 2862-2869.
20. Grosskopf, I., N. Baroukh, S. J. Lee, Y. Kamari, D. Harats, E. M. Rubin, L. A. Pennacchio, and A. D. Cooper. 2005. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler. Thromb. Vasc. Biol. 25: 2573-2579.
21. Lookene, A., J. A. Beckstead, S. Nilsson, G. Olivecrona, and R. O. Ryan. 2005. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J. Biol. Chem. 280: 25383-25387.
22. Merkel, M., and J. Heeren. 2005. Give me A5 for lipoprotein hydrolysis! J. Clin. Invest. 115: 2694-2696.
23. Baroukh, N., E. Bauge, J. Akiyama, J. Chang, V. Afzal, J. C. Fruchart, E. M. Rubin, J. Fruchart-Najib, and L. A. Pennacchio. 2004. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler. Thromb. Vasc. Biol. 24: 1297-1302.
24. Ishihara, M., T. Kujiraoka, T. Iwasaki, M. Nagano, M. Takano, J. Ishii, M. Tsuji, H. Ide, I. P. Miller, N. E. Miller, et al. 2005. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J. Lipid Res. 46: 2015-2022.
25. O'Brien, P. J., W. E. Alborn, J. H. Sloan, M. Ulmer, A. Boodhoo, M. D. Knierman, A. E. Schultze, and R. J. Konrad. 2005. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin. Chem. 51: 351-359.
26. Prieur, X., F. G. Schaap, H. Coste, and J. C. Rodriguez. 2005. Hepatocyte nuclear factor-4{alpha} regulates the human apolipoprotein AV gene: identification of a novel response element and involvement in the control by PGC-1{alpha}, AMP-activated protein kinase and MAP kinase pathway. Mol. Endocrinol. 19: 3107-3125.
27. Pruneta-Deloche, V., G. Ponsin, L. Groisne, J. Fruchart-Najib, M. Lagarde, and P. Moulin. 2005. Postprandial increase of plasma apoA-V concentrations in type 2 diabetic patients. Atherosclerosis. 181: 403-405.
28. Dorfmeister, B., S. Brandlhofer, F. G. Schaap, M. Hermann, C. Furnsinn, B. P. Hagerty, H. Stangl, W. Patsch, and W. Strobl. 2006. Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats. Diabetologia. 49: 1324-1332.
29. Becker, S., L. Schomburg, K. Renko, M. Tolle, M. van der Giet, and U. J. Tietge. 2006. Altered apolipoprotein A-V expression during the acute phase response is independent of plasma triglyceride levels in mice and humans. Biochem. Biophys. Res. Commun. 339: 833-839.
30. Dallinga-Thie, G. M., A. van Tol, H. Hattori, L. C. van Vark-van der Zee, H. Jansen, and E. J. Sijbrands. 2006. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia. 49: 1505-1511.
31. Vaessen, S. F., F. G. Schaap, J. A. Kuivenhoven, A. K. Groen, B. A. Hutten, S. M. Boekholdt, H. Hattori, M. S. Sandhu, S. A. Bingham, R. Luben, et al. Apolipoprotein AV, triglycerides and risk of future coronary artery disease in apparently healthy men and women: the Prospective Epic-Norfolk Population Study. J. Lipid Res. E-pub ahead of print. June 12, 2006; doi:10.1194/jlr. M600233-JLR200.
32. Henneman, P., F. G. Schaap, L. M. Havekes, P. C. Rensen, R. R. Frants, A. van Tol, H. Hattori, A. H. Smelt, and K. W. van Dijk. Plasma apoA-V levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis. E-pub ahead of print. June 12, 2006; doi:10.1016/j.atherosclerosis.2006.05.030.
33. Prieur, X., H. Coste, and J. C. Rodriguez. 2003. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J. Biol. Chem. 278: 25468-25480.
34. Vu-Dac, N., P. Gervois, H. Jakel, M. Nowak, E. Bauge, H. Dehondt, B. Staels, L. A. Pennacchio, E. M. Rubin, J. Fruchart-Najib, et al. 2003. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferatoractivated receptor alpha activators. J. Biol. Chem. 278: 17982-17985.
35. Schultze, A. E., W. E. Alborn, R. K. Newton, and R. J. Konrad. 2005. Administration of a PPARalpha agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio. J. Lipid Res. 46: 1591-1595.